Nuevo tratamiento topico para Vitiligo!

NEW THERAPEUTIC OPTION FOR VITILIGO

This proof-of-concept open-label clinical trial aimed to evaluate the role of ruxolitinib 1.5% cream (janus kinase inhibitor) in the treatment of vitiligo.

Twelve patients with at least 1% body area affected by vitiligo were included (54.5% men, mean age 52 years), although not all completed the study. All patients were submitted to a topical application of ruxolitinib 1.5% cream, twice a day, for 20 weeks. Results were measured by the percentage of improvement in VASI (Vitiligo Area Scoring Index) from baseline to week 20.

The results after 20 weeks indicated a 76% improvement in VASI on 4 patients with significant facial involvement at baseline (95% confidence interval, 53-99%, p = 0.001) and overall improvement of VASI of all participants (95% confidence interval, 4-4.43%, p = 0.02). Three out of 8 patients showed response in body areas and 1 out of 8 patients showed response on acral surface. The adverse events observed were mild and included erythema, hyperpigmentation and transient acne.

The authors concluded that, despite the limitations of an open study with a small sample, ruxolitinib 1.5% cream presented significant results in facial repigmentation and may be a new therapeutic option for vitiligo.

J Am Acad Dermatol. 2017 Apr 5. pii: S0190-9622(17)30301-8. doi:

10.1016/j.jaad.2017.02.049. [Epub ahead of print]

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib.

Rothstein B, Joshipura D, Saraiya A, Abdat R, Ashkar H, Turkowski Y, Sheth V, Huang V, Au SC, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D.

Benjamin Hidalgo-Matlock

Skin Care Physicians of Costa Rica

4000-1054

2208-8206

Please excuse the shortness of this message, as it has been sent from a mobile device.